What severe side effects does Yervoy cause most often?
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, triggers immune-related adverse events by overactivating the immune system against healthy tissues. Severe (Grade 3-4) side effects occur in about 25-40% of patients, with the most common being gastrointestinal, hepatic, skin, endocrine, and pulmonary issues.[1][2]
Most frequent severe side effects and rates
- Colitis or enterocolitis: Inflammation of the colon or intestines, affecting 7-10% severely; can lead to perforation or bleeding requiring hospitalization or surgery.[1][3]
- Hepatitis: Liver inflammation, in 1-5% of cases; marked by elevated enzymes, jaundice, or failure needing steroids or immunosuppressants.[2][4]
- Dermatitis or skin reactions: Severe rash or toxic epidermal necrolysis in 2-5%; often involves widespread blistering or ulceration.[1][3]
- Endocrinopathies: Hypophysitis (pituitary inflammation), thyroiditis, or adrenal insufficiency in 2-8%; causes hormone deficiencies managed with lifelong replacement therapy.[2][4]
- Pneumonitis: Lung inflammation in 1-3%; presents as shortness of breath or hypoxia, sometimes fatal if untreated.[1][3]
These rates come from pivotal trials like those for advanced melanoma, where 34% of monotherapy patients experienced Grade 3-4 events.[1]
How do these side effects happen and get managed?
Yervoy blocks CTLA-4, unleashing T-cells that attack tumors but also normal organs. Onset is typically 2-12 weeks after starting doses (3 mg/kg every 3 weeks).[2] Management starts with high-dose corticosteroids; 80-90% respond, but 20-30% need additional biologics like infliximab for colitis.[4] Fatalities occur in 1-2% overall, highest from colitis or pneumonitis.[3]
Side effects in combination therapy like Yervoy + Opdivo
When paired with nivolumab (Opdivo), severe events rise to 50-60%, with colitis (10-15%), hepatitis (5-10%), and pneumonitis (5-7%) leading. Trials show higher discontinuation rates (30-40%).[2][5]
What risks concern patients most?
Long-term issues include permanent endocrine damage (e.g., hypothyroidism in 15-20%) and rare neurologic events like Guillain-Barré (0.1-1%). Monitoring requires weekly bloodwork and imaging; patients report colitis as most disruptive, often delaying treatment.[4][6] Black box warning covers these immune effects.[1]
How common are they compared to chemo or other immunotherapies?
Yervoy's severe event rate (25-40%) exceeds traditional chemo (10-20%) but matches PD-1 inhibitors like Keytruda alone (15-25%). Combinations amplify risks.[2][5]
[1]: Yervoy Prescribing Information (FDA, 2023)
[2]: NEJM: Ipilimumab Trial (Hodi et al., 2010)
[3]: CheckMate Trials Summary (BMS Data)
[4]: ASCO Guidelines on Immune Checkpoint Toxicity (2021)
[5]: NEJM: Nivo+Ipi vs. Monotherapy (Larkin et al., 2015)
[6]: FDA Adverse Event Reporting (FAERS, 2023)